Cancer therapy
AssigneeProkarium Limited
InventorsLivija Deban, Hyam Levitsky
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of cancer therapy. In particular, the present invention relates to a live attenuated Gram-negative bacterium for use in the treatment, reduction, inhibition or control of a neoplastic disease in a subject undergoing or intended to undergo immunotherapy with a checkpoint inhibitor therapy, an adoptive T cell therapy and/or an allogeneic or an autologous CAR-T therapy simultaneously, separately or sequentially with the administration of the live attenuated Gram-negative bacterium.
Claims20
A method of treating, reducing, inhibiting or controlling a neoplastic disease in a subject undergoing or intended to undergo a checkpoint inhibitor therapy, an adoptive cell therapy and/or an allogenic or autologous CAR-T therapy, comprising administering simultaneously, separately or sequentially a live attenuated Gram-negative bacterium, wherein the live attenuated Gram-negative bacterium is orally administered, subcutaneously administered or intramuscularly administered.
Dependencies are inferred from the claim text.